NPI-2358 is a tubulin-depolymerizing agent: In-vitro evidence for activity as a tumor vascular-disrupting agent

Anti-Cancer Drugs

Volumn 17, Issue 1, 2006, Pages 25-31

  Nicholson, Benjamin ^a   Lloyd, G Kenneth ^a   Miller, Brian R ^a   Palladino, Michael A ^a   Kiso, Yoshiaki ^b   Hayashi, Yoshio ^b   Neuteboom, Saskia T C ^a  

^a Nereus Pharmaceuticals Inc   (United States)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Cancer; Natural product; NPI 2358; Tubulin depolymerizing agent; Vascular disrupting agent

Indexed keywords

COLCHICINE; COMBRETASTATIN A4; NATURAL PRODUCT; NPI 2350; NPI 2358; PIPERAZINEDIONE; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPERGILLUS; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG STRUCTURE; HUMAN; HUMAN CELL; LUNG CARCINOMA; MICROTUBULE ASSEMBLY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; VASCULAR TUMOR;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; COLCHICINE; DEXTRANS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FLUORESCEIN-5-ISOTHIOCYANATE; HL-60 CELLS; HT29 CELLS; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; JURKAT CELLS; MICROTUBULES; NEOPLASMS; PIPERAZINES; STILBENES; TIME FACTORS; TUBULIN; VINCRISTINE;

EID: 33646118484     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000182745.01612.8a     Document Type: Article

References (28)

1. Denekamp J. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993; 66:181-196.
2. Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumor vascular targeting agents. Int J Exp Pathol 2002; 83:21-38.
3. Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumor vascular targeting activity in vivo. Anticancer Res 2001; 21:93-102.
4. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002; 62:7247-7253.
5. Gotlieb AI. The endothelial cytoskeleton: organization in normal and regenerating endothelium. Toxicol Pathol 1990; 18:603-617.
6. Ingber DE, Prusty D, Sun Z, Betensky H, Wang N. Cell shape, cytoskeletal mechanics, and cell cycle control in angiogenesis. J Biomech 1995; 28:1471-1484.
7. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10:415-427.
8. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004; 100:2491-2499.
9. Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002; 99: 2060-2069.
10. Micheletti G, Poli M, Borsotti P, Martinelli M, Imberti B, Taraboletti G, et al. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 2003; 63:1534-1537.
11. Seed L, Slaughter DP, Limarzi LR. Effect of colchicine on human carcinoma. Surgery 1940; 7:696-709.
12. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Ag 2002; 2:1-17.
13. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloids: anti-vascular effects in a murine tumor. Eur J Cancer 1993; 29A:1320-1324.
14. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001; 61:6413-6422.
15. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997; 57:1829-1834.
16. Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002; 53:164-171.
17. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4:253-265.
18. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003; 94:15-21.
19. Harker WG, Slade DL, Drake FH, Parr RL. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry 1991; 30: 9953-9961.
20. Kanoh K, Kohno S, Asari T, Harada T, Katada J. (-)-Phenylahistin: a new mammalian cell cycle inhibitor produced by Aspergillus ustus. Bioorg Med Chem Lett 1997; 7:2847-2852.
21. Fairchild CR, Johnston KJ, Peterson RW, Cornell LA, Bifario M, Raventos-Suarez C, et al. Halimide, a novel cytotoxic marine natural product, destabilizes microtubules and demonstrates in vivo antitumor activity. Proc Am Ass Cancer Res 1998; 39:165.
22. Kanoh K, Kohno S, Katada J, Takahashi J, Uno I. (-)-Phenylahistin arrests cells in mitosis by inhibiting tubulin polymerization. J Antibiot (Tokyo) 1999; 52:134-141.
23. Kanoh K, Kohno S, Katada J, Hayashi Y, Muramatsu M, Uno I. Antitumor activity of phenylahistin in vitro and in vivo. Biosci Biotechnol Biochem 1999; 63:1130-1133.
24. Mitchell SS, Nicholson B, Teisan S, Lam KS, Potts BCM. Aureoverticillactam, a novel 22-atom macrocyclic lactam from the marine actinomycete Streptomyces aureoverticillatus. J Nat Prod 2004; 67: 1400-1402.
25. Watts ME, Woodcock M, Arnold S, Chaplin DJ. Effects of novel and conventional anti-cancer agents on human endothelial permeability: influence of tumor secreted factors. Anticancer Res 1997; 17: 71-75.
26. Hill SA, Tozer GM, Pettit GR, Chaplin DJ. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anticancer Res 2002; 22:1453-1458.
27. Sheng Y, Hua J, Pinney KG, Garner CM, Kane RR, Prezioso JA, et al. Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int J Cancer 2004; 111:604-610.
28. Lloyd GK, Nicholson B, Neuteboom STC, Marty J, Mangold G, Palladino MA. NPI-2358 and NPI-2386: Two new vascular/tubulin modifying agents greatly potentiate standard chemotherapy in xenograft models. Clin Cancer Res 2003; 9:6153s.